| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
Ultrasound creates transient permeability of cell membranes in the presence of nanobubbles or microbubbles, and foreign molecules can easily enter cells, which is known as ‘sonoporation’. We developed anti-Epitherial Growth Factor Receptor (EGFR) antibody conjugated MBs (EGFR-MB). We examined the effect of EGFR-MB on oral squamous cell carcinoma. MBs were conjugated with an anti-EGFR antibody, and were entrapped ultrasound contrast gas. Ca9-22, a human gingival carcinoma cell line, were exposed to ultrasound with EGFR-MB and anti-cancer drug bleomycin (BLM). Sonoporation and EGFR-MB had a strong cytotoxic effect on Ca9-22 cells at the low dose of BLM. In addition, sonoporation and EGFR-MB remarkably increased the population of apoptotic cells even at a low dose BLM.Treatment with EGFR-MB and ultrasound make it possible to administer drugs into the cells more efficiently and specifically, suggesting a novel application for chemotherapy treatment for oral squamous cell carcinoma.
|
